CD163 and diffuse large B-cell lymphoma: Nam et al. evaluated the amount of M2 macrophages in R-CHOP (Rituximab, C: Cyclophosphamide, H: Doxorubicin Hydrochloride, O: Vincristine Sulfate, P: Prednisolone) treated DLBCL patients and they found that the higher number of CD163+ and CD163/CD68 + cells ratio was significantly associated with shorter overall survival.